丹参酮IIA的抗肿瘤药理作用及其纳米给药系统研究进展  

Research Progress on Anti-tumor Efficacy and Nano-Sized Drug Delivery System of Tanshinone IIA

作　　者：乔利 韩茂森 高世杰[1] 明正 付先军[3] Qiao Li;Han Maosen;Gao Shijie;Ming Zheng;Fu Xianjun(Experimental Center,Shandong University of Traditional Chinese Medicine,Jinan 250355,China;International Office,Shandong University of Traditional Chinese Medicine,Jinan 250355,China;Laboratory of Traditional Chinese Medicine Network Pharmacology,Shandong University of Traditional Chinese Medicine,Jinan 250355,China)

机构地区：[1]山东中医药大学实验中心,济南250355 [2]山东中医药大学国际交流与合作处,济南250355 [3]山东中医药大学中药网络药理学实验室,济南250355

出　　处：《世界科学技术-中医药现代化》2020年第11期3919-3927,共9页Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology

基　　金：山东省自然科学基金委员会项目(ZR2019PH048):跨血脑屏障丹参酮IIA脂质体体系的制备及其脑胶质瘤靶向治疗研究,负责人:乔利;国家科学技术部国家重点研发计划项目(2017YFC1702703):丹参核心功效与生物学机制研究,负责人:付先军;山东中医药大学仪器开发专项项目(2018yq18):基质辅助激光解析飞行时间质谱仪技术性能开发与应用,负责人:乔利。

摘　　要：近年来,肿瘤发病率不断攀升,化疗是目前临床治疗肿瘤的主要策略,但因多数化疗药物毒副作用大且容易造成化学耐药性,导致化疗效果并不理想。而传统中药凭借其多途径、多靶点、多通路的特点在抗肿瘤方面具有治疗温和不剧烈、毒副作用小等独特的优势。丹参酮IIA(Tanshinone IIA,TSA)作为丹参中提取的主要菲醌类衍生物,具有明显的抗肿瘤作用,具备被开发为毒性小、疗效好的新型抗肿瘤药物的条件,但因其难溶于水、半衰期短、生物利用度低等缺点极大程度上限制了其临床应用。利用纳米技术,可以改善丹参酮IIA的不足;构建中药纳米递药系统可以提高肿瘤组织靶向性来改善半衰期短、稳定性差等实际临床应用中的问题。本文主要综述丹参酮IIA的抗肿瘤机理及其纳米递药系统的研究进展,以期为丹参酮IIA的深入研究和临床应用提供参考。In recent years, the incidence of tumors has been increasing. Chemotherapy is the main clinical strategy for the treatment of tumors at present. Most of the chemotherapeutic drugs have serious side effects and tend to cause chemical resistance, so chemotherapy is not an ideal choice. Traditional Chinese medicine(TCM) has unique advantages, such as mild and non-violent treatment and low toxic and side effects in terms of anti-tumor due to its multi-path, multi-target and multi-path characteristics. Tanshinone IIA, as the main phenanthrene derivative extracted from Salvia miltiorrhiza Bge, has an obvious anti-tumor effect and has the conditions to be developed as a new antitumor drug with low toxicity and good efficacy. However, it is insoluble in water and has a short half-life period, low bioavailability, and other shortcomings, which makes its clinical application greatly limited. The use of nanotechnology can fix those problems of tanshinone IIA;the construction of a TCM nano-delivery system can improve the targeting of tumor tissues to improve the problems in practical clinical applications, such as short half-life and poor stability. This article reviewed the anti-tumor mechanism of tanshinone IIA and the research progress of its nano-delivery system,providing references for the in-depth research and clinical application of tanshinone IIA.

关 键 词：丹参酮IIA 抗肿瘤 生物利用度 纳米递药 

分 类 号：R273[医药卫生—中西医结合]